Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Acer Therapeutics Inc is a biotechnology business based in the US. Acer Therapeutics shares (ACER) are listed on the NASDAQ and all prices are listed in US Dollars. Acer Therapeutics employs 30 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $2.12 |
|---|---|
| 52-week range | $1.68 - $5.39 |
| 50-day moving average | $2.25 |
| 200-day moving average | $2.56 |
| Wall St. target price | $11.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.24 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.12 from 2022-01-21
| 1 week (2022-01-13) | -5.78% |
|---|---|
| 1 month (2021-12-18) | N/A |
| 3 months (2021-10-18) | N/A |
| 6 months (2021-07-22) | -12.40% |
| 1 year (2021-01-22) | -42.23% |
|---|---|
| 2 years (2020-01-22) | -52.89% |
| 3 years (2019-01-22) | 24.8 |
| 5 years (2017-01-20) | 134.25% |
| Revenue TTM | $900,000 |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -45.87% |
| Return on equity TTM | -271.41% |
| Profit margin | 0% |
| Book value | $0.15 |
| Market capitalisation | $31.6 million |
TTM: trailing 12 months
We're not expecting Acer Therapeutics to pay a dividend over the next 12 months.
Acer Therapeutics's shares were split on a 96:1000 basis on 20 September 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 96 shares. This wouldn't directly have changed the overall worth of your Acer Therapeutics shares – just the quantity. However, indirectly, the new 941.7% higher share price could have impacted the market appetite for Acer Therapeutics shares which in turn could have impacted Acer Therapeutics's share price.
Over the last 12 months, Acer Therapeutics's shares have ranged in value from as little as $1.68 up to $5.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acer Therapeutics's is 1.1061. This would suggest that Acer Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Acer Therapeutics Inc. , a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 1991 and is headquartered in Newton, Massachusetts. .
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.